Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Price Target of $6.67 According to Analysts

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) has received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $6.67.

IPHA has been the subject of a number of recent analyst reports. Leerink Partners upgraded shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target for the company in a report on Tuesday, August 11th. BTIG Research reissued a “buy” rating and set a $9.00 price target on shares of Innate Pharma in a research report on Thursday, September 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Innate Pharma in a report on Tuesday, September 22nd. UBS Group reissued a “buy” rating on shares of Innate Pharma in a report on Tuesday, August 11th. Finally, Citigroup upgraded shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th.

Innate Pharma Price Performance

NASDAQ:IPHA opened at $1.50 on Friday. Innate Pharma has a fifty-two week low of $1.17 and a fifty-two week high of $2.71. The business has a 50 day moving average price of $1.83 and a 200-day moving average price of $1.77.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company researches treatments designed to activate or enhance the immune system’s ability to recognize and eliminate tumor cells, with an emphasis on natural killer cells and other components of the innate immune system.

Its pipeline includes lacutamab, an antibody directed at KIR3DL2 that is being studied in certain forms of cutaneous T-cell lymphoma. Innate Pharma has also developed monalizumab, an antibody targeting the NKG2A immune checkpoint, through a collaboration with AstraZeneca.